Exploring the Efficacy of Tislelizumab Combined With Albumin-bound Paclitaxel and Platinum-based Chemotherapy in Patients With KRAS-mutated Lung Cancer Who Are Ineligible for Curative Surgery

Guangzhou Medical University1 个研究点分布在 1 个国家目标入组 30 人开始时间: 2020年11月6日最近更新: 2026年6月10日

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 30
试验地点: 1

研究概览研究设计入排标准研究者研究点记录与标识符相似试验

研究概览

简要总结

To determine the optimal objective response rate (ORR) of tislelizumab combined with albumin-bound paclitaxel and platinum agents in patients with KRAS-mutant lung cancer who are ineligible for curative surgery

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Other

入排标准

年龄范围: 18 Years 至 75 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Ages 18-75 years (inclusive), regardless of gender;
•Locally advanced (Stage IIIB, IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) confirmed by histology as inoperable for curative intent (according to the 8th edition of the IASLC TNM staging system);
•Or histologically confirmed inoperable mixed small cell lung cancer containing non-small cell lung cancer components;
•KRAS gene mutation-positive;
•KRAS mutation-positive lung cancer not amenable to radical surgery, treated with tislelizumab in combination with nab-paclitaxel and platinum chemotherapy.

排除标准

•Patients with incomplete key baseline information and treatment data.
•Patients who refuse to provide written informed consent (ICF).

研究者

发起方

Guangzhou Medical University

申办方类型

Other

责任方

Principal Investigator

主要研究者

Haihong Yang, MD, Pricipal investigator

Chief Physician

Guangzhou Medical University

研究点 (1)

Loading locations...

相似试验

招募中

2 期

Phase II study: efficacy and safety of tislelizumab in patients with de novo Hodgkin lymphoma unsuitable for standard chemotherapyHodgkin lymphoma

2022-503090-11-00Fondazione Italiana Linfomi Onlus25

招募中

2 期

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United StatesAdvanced Unresectable Gastric AdenocarcinomaEsophageal Squamous Cell CarcinomaAdvanced Gastroesophageal Adenocarcinoma

NCT07554521BeOne Medicines30

招募中

2 期

Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ AdenocarcinomaGastric or Esophagogastric Junction Adenocarcinoma

NCT07569068Ruijin Hospital88

招募中

3 期

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

NCT07385703Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.752

尚未招募

2 期

Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma

NCT07388758Sun Yat-sen University37